JHM Biopharmaceutical (Hangzhou) Co., Ltd.（"JHM") today announced the enrollment of its first patient in a clinical trial of its innovative, patented Recombinant Type A Botulinum Toxin. The trial, led by Huashan Hospital (affiliated to Fudan University), marks the official launch of neurological research in China using this treatment for adult stroke patients who suffer from upper limb spasticity.
JHM Biopharmaceutical Begins Clinical Trial of its RecombinantJHM Biopharma (Hangzhou) Co., Ltd. ("JHM") today announced that it has successfully completed a Series B+ financing round of over CN¥200 million, following its CN¥100 million Series B round in May.
The total funding raised has now reached close to CN¥350 million. SDIC Unity Capital led the Series B+ round, with participation from Hongsheng Capital, Oriza Holdings, and Soyoung Group. WinX Capital served as the exclusive financial advisor. The funds raised in this round will be primarily used to support the development of JHM’s product pipeline, deepen its presence in therapeutic and consumer health markets, and accelerate commercialization.
5F, Tower 9, Hexiang Science Centre,
+86 (571) 8888 3223Hotline：4008081899No.2177 Tuanjie Rd. Kaui Damao Town, Tonghua+86 (435) 508 8818
info@jhm-biopharma.com5F, Tower 9, Hexiang Science Centre,+86 (571) 8888 3223No.2177 Tuanjie Rd. Kaui Damao Town, Tonghua+86 (435) 508 8818Hotline：4008081899info@jhm-biopharma.com